Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Male Infertility AND Infertility

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44349   clinical trials with a EudraCT protocol, of which   7376   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    127 result(s) found for: Male Infertility AND Infertility. Displaying page 3 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2004-001361-18 Sponsor Protocol Number: CERL080ABE01 Start Date*: 2004-09-28
    Sponsor Name:Novartis Pharma N.V.
    Full Title: Conversion trial from Cellcept® (MMF) to myfortic® (enteric-coated MPA) in stable transplanted patients suffering from GI adverse events while on Cellcept® therapy.
    Medical condition: liver or kidney transplant - stable
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007055-13 Sponsor Protocol Number: CTU 043C Start Date*: 2009-07-17
    Sponsor Name:RIEMSER Arzneimittel AG
    Full Title: DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED PROSPECTIVE MULTI-CENTRE PHASE III TRIAL TO ASSESS THE EFFICACY AND SAFETY OF METHANTHELINIUM BROMIDE (VAGANTIN®) IN THE TREATMENT OF FOCAL PALMAR-AXILL...
    Medical condition: Treatment of patients with axillary and palmar hyperhidrosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005309-28 Sponsor Protocol Number: APHP200031 Start Date*: 2023-04-07
    Sponsor Name:Assistance Publique des Hôpitaux de Paris
    Full Title: Efficacy of certolizumab in women with unexplained recurrent implantation failure: a double-blind randomized controlled trial - CERTIFY
    Medical condition: Adult women with recurrent implantation failures
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-003993-42 Sponsor Protocol Number: PKB171-02 Start Date*: 2017-03-17
    Sponsor Name:Prokrea BCN S.L.
    Full Title: A multi-centre, randomised, double-blind, placebo-controlled trial to investigate the efficacy and safety of two concentrations of PKB171 against placebo in couples with asthenozoospermia who wish ...
    Medical condition: Asthenozoospermia
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004266-15 Sponsor Protocol Number: ARYHM-1 Start Date*: 2012-01-18
    Sponsor Name:RMC, Skåne University Hospital
    Full Title: Androgen replacement in young hypogonadal men: a 2 year randomized, double-blind placebo controlled study
    Medical condition: Target population: Male hypogonadism (testosterone deficiency) As end points Bone mineralisation Body composition Markers of insulin sensitivity and cardiovascular disease Lipid profile H...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10067734 Testosterone deficiency LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Ongoing) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001105-81 Sponsor Protocol Number: ACT-CYC-300-2013-01 Start Date*: 2013-07-31
    Sponsor Name:Actavis Group PTC ehf.
    Full Title: Randomized Clinical Trial to Compare the Pregnancy Rates of Vaginally Applied Cyclogest® Pessary and Crinone® 8% Gel After In-vitro Fertilization
    Medical condition: Luteal phase support after IVF
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) BE (Completed) BG (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2007-003938-41 Sponsor Protocol Number: IMP 28364 Start Date*: 2007-09-25
    Sponsor Name:Merck Lipha Santé SAS
    Full Title: Open label pilot study on gene expression profiling of the endometrial tissue in patients undergoing Assisted Reproductive Technology (ART: only IVF) with GONAL-f.
    Medical condition: This study will be conducted in infertile women justifying ART (Assisted Reproductive Technology) treatment (only IVF - In Vitro Fecondation)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056204 In vitro fertilisation LLT
    Population Age: Adults Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004458-27 Sponsor Protocol Number: Krypto-3 Start Date*: 2021-01-21
    Sponsor Name:Rigshospitalet
    Full Title: Optimizing the fertility potential of bilateral cryptorchidism by treatment with adjuvant kryptocur.
    Medical condition: Cryptorchidism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10056600 Cryptorchidism LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002498-36 Sponsor Protocol Number: CCN017 Start Date*: 2018-10-12
    Sponsor Name:National Institutes of Health - Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Full Title: Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception
    Medical condition: As the clinical trial is intended to investigate a new contraceptive medicinal product, the trial subjects included are not characterized by a specific medical condition.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10065589 Male contraception PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011212-37 Sponsor Protocol Number: RD.03.SPR.29084 Start Date*: 2010-01-06
    Sponsor Name:Galderma research & Development
    Full Title: Anti P. acnes activity of Epiduo® Gel compared to Benzoyl Peroxide 2.5% Gel in the treatment of subjects with acne vulgaris
    Medical condition: Acne vulgaris with a high level of P. Acnes on the face (obeserved under wood's lamp)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10000519 Acne vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-000500-83 Sponsor Protocol Number: 2-55-52060-002 Start Date*: 2008-07-15
    Sponsor Name:Ipsen Pharma
    Full Title: A phase II exploratory, ascending dose, multicentre study to investigate the pharmacodynamics, pharmacokinetics, safety and tolerability, of BIM23A760 in acromegalic patients.
    Medical condition: Acromegaly
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000599 Acromegaly LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) BE (Completed) IT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2013-000993-32 Sponsor Protocol Number: S55300 Start Date*: 2013-05-07
    Sponsor Name:University Hospital Leuven
    Full Title: Does prolonged GnRH downregulation prior to ART improve the clinical pregnancy rate in postoperative endometriosis patients? A RCT
    Medical condition: endometriosis, subfertility
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004872 10042392 Subfertility (female) LLT
    15.1 100000004872 10014789 Endometriosis, site unspecified LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001160-29 Sponsor Protocol Number: NAL-II-19-1 Start Date*: 2019-06-24
    Sponsor Name:LABORATOIRES SMB S.A
    Full Title: A single blind, placebo controlled, three period, chronic dosing (6 weeks), multicentre, exploratory study to evaluate the effects of Nacystelyn (20 mg BID and 40 mg BID) on Functional Respiratory ...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-006055-52 Sponsor Protocol Number: CRAD001JDE15T Start Date*: 2009-01-09
    Sponsor Name:Charité - University Hospital of Berlin
    Full Title: Everolimus (RAD001) in combination with intravenous carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer
    Medical condition: Breast cancer is the most prevalent malignancy in women and metastatic breast cancer is a leading cause of mortality, accounting for more than 400,000 deaths annually worldwide. Even though anthrac...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000909-28 Sponsor Protocol Number: 64007957MMY3005 Start Date*: 2022-09-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Dar...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000995-33 Sponsor Protocol Number: EuroNet-PHL-C1 Start Date*: 2006-12-13
    Sponsor Name:Martin-Luther-University Halle-Wittenberg
    Full Title: EuroNet-Paediatric Hodgkin’s Lymphoma Group First international Inter-Group Study for classical Hodgkin’s Lymphoma in Children and Adolescents
    Medical condition: 1st and 2nd line therapy for childhood Hodgkin’s lymphoma shall be further optimised to avoid over-treatment and decrease long-term complications.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) GB (Completed) SE (Completed) AT (Completed) FR (Completed) IE (Completed) ES (Completed) DK (Completed) PL (Completed) BE (Completed) NL (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2013-000081-11 Sponsor Protocol Number: BFS-AS-306 Start Date*: 2013-05-28
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A 12-Week Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients with Persistent As...
    Medical condition: Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) AT (Completed) DE (Completed) BE (Completed) IT (Completed) SE (Completed) CZ (Completed) FI (Completed) ES (Completed) PL (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-000812-29 Sponsor Protocol Number: AMB 320 Start Date*: 2005-09-21
    Sponsor Name:Myogen, Inc.
    Full Title: Ambrisentan in PAH - A Phase III, Randomised, Double- Blind, Placebo- Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037400 low
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) BE (Completed) IT (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001737-27 Sponsor Protocol Number: 54767414AMY3001 Start Date*: 2018-04-16
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnos...
    Medical condition: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis )
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002207-36 Sponsor Protocol Number: INCB54828-801 Start Date*: 2021-11-15
    Sponsor Name:INCYTE CORPORATION
    Full Title: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib
    Medical condition: Male and female participants at least 18 years of age who are actively receiving treatment with pemigatinib under a parent protocol and receiving clinical benefit and who do not have access to pemi...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) DK (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 18 06:25:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA